SCHEMBL7002587

SCHEMBL7002587

c1cnc2[nH]c(Cc3nc4cccnc4[nH]3)nc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.42
ALDH1A1 P00352 2/20 0.40
CCNB2 O95067 1/20 0.40
CDK1 P06493 1/20 0.40
CCNB1 P14635 1/20 0.40
GSK3B P49841 1/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40
CCNB3 Q8WWL7 1/20 0.40
PKM P14618 1/20 0.40
AXL P30530 1/20 0.39
NUDT1 P36639 1/20 0.39
GPR84 Q9NQS5 1/20 0.39
KMT2A Q03164 1/20 0.39
EGFR P00533 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
LMNA P02545 2/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6994153 0.90 GAA (0.58) GAAPKMEGFRNPC1RAB9A
SCHEMBL6948812 0.85 PKM (0.58) GAAALDH1A1PKMAXLNUDT1
SCHEMBL4361327 0.85 DDAH1 (0.55) GAAALDH1A1PKMAXLNUDT1
SCHEMBL4333658 0.85 ALDH1A1 (0.38) ALDH1A1CCNB2CDK1CCNB1GSK3B
SCHEMBL4347806 0.85 RIPK1 (0.43) GAAALDH1A1AXLNUDT1KMT2A
SCHEMBL2972100 0.85 ALDH1A1 (0.38) ALDH1A1CCNB2CDK1CCNB1GSK3B
SCHEMBL5264712 0.85 ALDH1A1 (0.38) ALDH1A1CCNB2CDK1CCNB1GSK3B
SCHEMBL18291869 0.85 ALDH1A1 (0.38) ALDH1A1CCNB2CDK1CCNB1GSK3B
SCHEMBL8288254 0.85 MAPT (0.40) ALDH1A1CCNB2CDK1CCNB1GSK3B
Hydrochloric Acid SCHEMBL4472373 0.83 PKM (0.37) ALDH1A1CCNB2CDK1CCNB1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541486-B1 Used for treating ischemia, such as results from stroke or myocardial infarction, trauma, neurodegeneration, and inflammation. ELAN PHARMA INTERNATIONAL LTD. (IE) 2003-04-01 US claimed
EP-1189889-B1 COMPOSITIONS AND METHODS FOR INHIBITING CELL DEATH ELAN PHARMA INT LTD (IE) 2003-12-17 EP disclosed
US-6541486-B1 Used for treating ischemia, such as results from stroke or myocardial infarction, trauma, neurodegeneration, and inflammation. ELAN PHARMA INTERNATIONAL LTD. (IE) 2003-04-01 US disclosed